Biopharmaceutical CMO And CRO Market Size Worth $54.1 Billion By 2030: Grand View Research, Inc.

SAN FRANCISCO, Feb. 8, 2022 /PRNewswire/ -- The global biopharmaceutical CMO and CRO market size is expected to reach USD 54.1 billion by 2030, registering a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Post-pandemic the market is being driven by the growing interest of conventional drug developers in the biological therapeutics. At present, outsourcing has become a cost-saving strategy for small- to medium-sized biomanufacturers, as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel. The post-pandemic recovery has started owing to positive pipeline developments across modalities.

Key Insights & Findings from the report:

• Non-mammalian cell line-based bioproduction system is expected to be the fastest-growing segment over the forecast period
• Innovative strategies are being implemented to identify and explore the potential of various microbes
• This can be attributed to increasing investments in research programs for the development of novel therapeutics
• The market in North America is recognized as a leader in biopharmaceutical innovations, thereby resulting in a large share of 33.97%
• Moreover, the presence of several service providers and a higher concentration & number of biopharmaceutical firms in the region supports the market growth
• The key players are involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities

Read 180 page market research report, "Biopharmaceutical CMO And CRO Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service (Contract Manufacturing, Contract Research), By Product, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

For instance, Lonza and Moderna announced a ten-year collaboration for the commercial manufacturing of the COVID-19 vaccine. Such developments compensated for minor delays in clinical trials that occurred during the first half of 2020. The contract manufacturing organization segment is projected to unlock lucrative growth opportunities over the foreseeable future. The decline in R&D productivity and increased development costs have resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the CMOs & CROs to accelerate their business operations.

The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs. However, these CMOs & CROs are expected to face competition from in-house departments of pharmaceutical & biotechnology companies. Several big pharma companies like Novartis announced to maintain and expand their biomanufacturing processes in-house over the coming years.

Market Segmentation:

Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source, service, product, and region:

• Biopharmaceutical CMO & CRO Source Outlook (Revenue, USD Million, 2017 - 2030)
• Mammalian
• Non-mammalian
• Biopharmaceutical CMO & CRO Service Outlook (Revenue, USD Million, 2017 - 2030)
• Contract Manufacturing
• Process Development
• Downstream
• Upstream
• Fill & Finish Operations
• Analytical & QC Studies
• Packaging
• Contract Research
• Oncology
• Inflammation & Immunology
• Cardiology
• Neuroscience
• Others
• Biopharmaceutical CMO & CRO Product Outlook (Revenue, USD Million, 2017 - 2030)
• Biologics
• Monoclonal antibodies (MAbs)
• Recombinant Proteins
• Vaccines
• Antisense, RNAi, & Molecular Therapy
• Others
• Biosimilars
• Biopharmaceutical CMO & CRO Regional Outlook (Revenue, USD Million, 2017 - 2030)
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• Asia Pacific
• China
• India
• Latin America
• Brazil
• Middle East & Africa
• South Africa

List of Key Players of Biopharmaceutical CMO & CRO Market

• Boehringer Ingelheim GmbH
• Lonza Group AG
• Inno Biologics Sdn Bhd
• Rentschler Biopharma SE
• JRS Pharma
• Biomeva GmbH
• ProBioGen AG
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Toyobo Co., Ltd.
• Samsung Biologics

Check out more studies related to biopharmaceuticals, published by Grand View Research:

• Biopharmaceutical Market – The global biopharmaceutical market is expected to witness significant growth over the forecast period. Biopharmaceuticals are drugs used for medical purposes and are produced by the extraction of proteins and nucleic acids direct from the biological source using biotechnology.
• Biopharmaceutical Excipients Market – The global biopharmaceutical excipients market size was valued at USD 2.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.5% from 2021 to 2028. Excipients play an essential role in biopharmaceuticals by helping the efficient binding of ingredients, modifying the solubility and bioavailability of API, and increasing drug stability in the dosage form.
• Biopharmaceutical Third Party Logistics Market – The global biopharmaceutical third party logistics market size was estimated at USD 94.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.6% from 2021 to 2028. The rising trend of outsourcing logistics, the focus of pharmaceutical players on their distribution network owing to its strong sales numbers, and the rise in the number of biosimilar launches are some of the key factors driving the market.

Browse through Grand View Research's coverage of the Global Medical Devices Industry.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Grand View Pipeline
Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.